Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo across selected Latin American markets. The agreement grants Knight Therapeutics rights to market the medicine for mycosis fungoides and Sézary syndrome subtypes. The arrangement marks Kyowa Kirin’s first commercial partnership for mogamulizumab in Latin America. Credit: agustin.photo/Shutterstock.com. Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab) across selected Latin American markets. Under the terms of the transaction, Knight Therapeutics will oversee regulatory submissions and commercial distribution of the therapy across Brazil, Argentina, Mexico, and Colombia.…

Source: Pharmaceutical Technology